Skip to main content

Advertisement

SpringerLink
Log in

Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: No time to lose

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Treatment guidelines have recently become more definitive regarding the optimal timing for initiation of combination antiretroviral therapy (ART) in the setting of an acute AIDS-related opportunistic infection (OI). These recent changes reflect new data from a prospective, randomized study and several retrospective studies, all of which support earlier initiation of ART during an OI. These studies focus on OIs for which effective antimicrobial therapy exists. For AIDS-related conditions that lack effective antimicrobial therapy, there are few studies to help inform the optimal timing to initiate ART, but most clinicians initiate ART early, as little else can be offered to these patients. For patients with HIV admitted for non-AIDS-related conditions, there are few data that directly address the optimal timing for ART. Initiating ART in the hospitalized patient can be challenging and requires a well-coordinated multidisciplinary team with expertise in ART management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mocroft A, Vella S, Benfield TL, et al.: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725–1730.

    Article  CAS  PubMed  Google Scholar 

  2. Palella FJJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.

    Article  PubMed  Google Scholar 

  3. Buchacz K, Baker RK, Moorman AC, et al.: Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS 2008, 22:1345–1354.

    Article  PubMed  Google Scholar 

  4. Recommendations of the National Institutes of Health, the Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Diseases Society of America: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. June 18, 2008. Available at http://aidsinfo.nih.gov/content-files/Adult_OI.pdf. Accessed November 18, 2008.

  5. Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group: British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563–608.

    Article  CAS  PubMed  Google Scholar 

  6. Dean GL, Edwards SG, Ives NJ, et al.: Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002, 16:75–83.

    Article  CAS  PubMed  Google Scholar 

  7. Shelburne SA, Visnegarwala F, Darcourt J, et al.: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005, 19:399–406.

    Article  PubMed  Google Scholar 

  8. Zolopa A, Anderson J, Komarow L, et al.: Immediate vs. deferred ART in the setting of an acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG 5164. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.

  9. Breton G, Duval X, Estellat C, et al.: Determinants of immune reconstitution inflammatory syndrome in HIV type-1 infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004, 39:1709–1712.

    Article  PubMed  Google Scholar 

  10. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ: Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006, 42:418–427.

    Article  CAS  PubMed  Google Scholar 

  11. Murdoch DM, Venter W, Feldman C, Van Rie A: Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008, 22:601–610.

    Article  CAS  PubMed  Google Scholar 

  12. Park WB, Choe PG, Jo JH, et al.: Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS 2006, 20:2390–2392.

    Article  PubMed  Google Scholar 

  13. Centre for the AIDS Programme of Research in South Africa: Press Release—Important New Research Findings on Treatment of TB-HIV Co-Infection. Available at http:// www.caprisa.org. Accessed November 12, 2008.

  14. ClinicalTrials.Gov. Available at http://clinicaltrials. gov/ct2/results?term=tuberculosis+AND+HIV. Accessed December 2, 2008.

  15. Morris A, Wachter RM, Luce J, et al.: Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003, 17:73–80.

    Article  PubMed  Google Scholar 

  16. Bisson GP, Nthobatsong R, Thakur R, et al.: The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswanna. J Acquir Immune Defic Syndr 2008, 49:227–229.

    Article  PubMed  Google Scholar 

  17. May M, Sterne JA, Sabin C, et al.: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21:1185–1197.

    Article  PubMed  Google Scholar 

  18. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al.: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283–2296.

    Article  Google Scholar 

  19. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed November 18, 2008.

  20. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555–570.

    Article  CAS  PubMed  Google Scholar 

  21. Giardi E, Sabin S, Monforte A: Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007, 46:S3–S8.

    Article  Google Scholar 

  22. Sabin CA, Smith CJ, Gumley H, et al.: Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004, 18:2145–2151.

    Article  PubMed  Google Scholar 

  23. Chadborn TR, Baster K, Delpech VC, et al.: No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993–2002). AIDS 2005, 19:513–520.

    Article  PubMed  Google Scholar 

  24. Murri R, Ammassari A, Trotta M, et al.: Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004, 19:1104–1110.

    Article  PubMed  Google Scholar 

  25. Ammassari A, Trotta MP, Murri R, et al.: Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002, 31:S123–S127.

    PubMed  Google Scholar 

  26. Howard AA, Arnsten JH, Lo Y, et al.: A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002, 16:2175–2182.

    Article  CAS  PubMed  Google Scholar 

  27. Gardner EM, Sharma S, Peng G, et al.: Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008, 22:75–82.

    Article  CAS  PubMed  Google Scholar 

  28. National HIV/AIDS Clinicians’ Consultation Center: Dosage form modifications and renal/hepatic dosing of antiretrovirals. Available at http://www.nccc.ucsf. edu/Clinical_Resources/Pharmacy/PDFs/4-07 HIV Dosage Table.pdf. Accessed November 18, 2008.

  29. Huang L, Quartin A, Jones D, Havlir DV: Intensive care of patients with HIV infection. N Engl J Med 2006, 355:173–181.

    Article  CAS  PubMed  Google Scholar 

  30. Kitahata MM, Koepsell TD, Deyo RA, et al.: Physicians’ experience with the acquired immunodeficiency syndrome as a factor in patients’ survival. N Engl J Med 1996, 334:701–706.

    Article  CAS  PubMed  Google Scholar 

  31. Bennett CL, Garfinkle JB, Greenfield S, et al.: The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA 1989, 261:2975–2979.

    Article  CAS  PubMed  Google Scholar 

  32. Sax PE, Islam R, Walensky RP, et al.: Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005, 41:1316–1323.

    Article  PubMed  Google Scholar 

  33. Weinstock HS, Zaidi I, Heneine W, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004, 189:2174–2180.

    Article  PubMed  Google Scholar 

  34. Novak RM, Chen L, MacArthur RD, et al.: Prevalence of antiretroviral drug resistance mutations in chronically HIVinfected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005, 40:468–474.

    Article  CAS  PubMed  Google Scholar 

  35. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005, 192:958–966.

    Article  PubMed  Google Scholar 

  36. Wheeler W, Mahle K, Bodnar U, et al.: Antiretroviral drug-resistance mutations and subtypes in drug-naïve persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.

  37. Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251–260.

    Article  CAS  PubMed  Google Scholar 

  38. Ribaudo HJ, Kuritzkes DR, Lalama CM, et al.: Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008, 197:1006–1010.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases and Geographic Medicine, 300 Pasteur Drive, Room S-101, Stanford, CA, 94305-5107, USA

    Philip Grant

Authors
  1. Philip Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Zolopa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Grant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grant, P., Zolopa, A. Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: No time to lose. Curr HIV/AIDS Rep 6, 63–67 (2009). https://doi.org/10.1007/s11904-009-0010-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-009-0010-3

Keywords

Search

Navigation